Indonesia Pharmaceuticals and Healthcare Report Q4 2017
Indonesia's pharmaceutical market will continue to be of interest to foreign companies. Maindraws include a large and growing population, increased per capita disposable income and gradualimprovements in the country's business climate. On the other hand, the country's patent protection remainsbelow par, which will hamper investment into the patented drug segment, as will concerns over financialviability over the universal healthcare coverage scheme.
Headline Expenditure Projections
Pharmaceuticals: IDR85.6trn (USD6.4bn) in 2016 to IDR94.2trn (USD7.0bn) in 2017; +10.2% growthin local currency terms and +8.3% in US dollar terms.
Healthcare: IDR363.7trn (USD27.329.bn) in 2016 to IDR403.1trn (USD29.8bn) in 2017; +10.5%growth in local currency terms and +9.0% in US dollar terms.